Roche: collaboration agreement with Replimune in cancer

(CercleFinance.com) - On Wednesday US biotech company Replimune announced that it has signed a collaboration agreement with Roche to develop new treatments for colorectal cancer and liver cancer.


Specifically, both partners intend to work together on the development of a third-line treatment for colorectal cancer and first- and second-line treatments for hepatocellular carcinoma.

Under the terms of the agreement, they will share the costs of the project, which will combine two Roche anti-cancer drugs (Tecentriq and Avastin) with Replimune's current RP2 and RP3 programs.


Copyright (c) 2022 CercleFinance.com. All rights reserved.